After Oppenheimer and H.C. Wainwright gave Gamida Cell (NASDAQ: GMDA) a Buy rating last month, the company received another Buy, this time from Needham. Analyst Chad Messer assigned a Buy rating to Gamida Cell today and set a price target of $17.00. The company’s shares closed last Friday at $6.97, close to its 52-week high of $7.70.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 11.9% and a 50.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Gamida Cell is a Strong Buy with an average price target of $16.25, which is a 141.5% upside from current levels. In a report issued on December 3, RBC Capital also maintained a Buy rating on the stock with a $13.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.70 and a one-year low of $2.60. Currently, Gamida Cell has an average volume of 252.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gamida Cell Ltd. is a clinical stage biopharmaceutical company engaging in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
